The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a ...
The FDA has approved berotralstat oral pellets for prophylactic use in patients aged 2 to than 12 years with hereditary ...
Patna: The National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, on Friday inked a memorandum of ...
Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at Rs 8,800 a month or four ...
The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent ...
Brent Saunders returned to Bausch + Lomb in 2023 to help address unmet needs in eye care, focusing on innovation and ...
BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to children ages 2 to under 12.
Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' drug to include an oral pellet ...
The 2024–2025 formulations of COVID-19 vaccines had an effectiveness rate of 76% at preventing emergency or urgent care ...
TipRanks on MSN
BioCryst gains FDA approval for pediatric HAE drug
BioCryst ( ($BCRX) ) has provided an announcement. On December 12, 2025, BioCryst Pharmaceuticals announced the FDA approval of its new drug ...
The US Food and Drug Administration (FDA) agency is proposing to add bemotrizinol as a permitted active ingredient for use in ...
ORLADEYO is now the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and above. A capsule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback